Result Number | Material Type | Add to My Shelf Action | Record Details and Options |
---|---|---|---|
1 |
Material Type: Article
|
Patlak Slope versus Standardized Uptake Value Image Quality in an Oncologic PET/CT Population: A Prospective Cross-Sectional StudyDiagnostics (Basel), 2024-05, Vol.14 (9), p.883 [Peer Reviewed Journal]COPYRIGHT 2024 MDPI AG ;2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;ISSN: 2075-4418 ;EISSN: 2075-4418 ;DOI: 10.3390/diagnostics14090883 ;PMID: 38732298Full text available |
|
2 |
Material Type: Article
|
Editorial: Bridging the gap to molecular imaging and theranosticsFrontiers in nuclear medicine, 2024-04, Vol.4 [Peer Reviewed Journal]EISSN: 2673-8880 ;DOI: 10.3389/fnume.2024.1385097Full text available |
|
3 |
Material Type: Book
|
Beyond Becquerel and Biology to Precision Radiomolecular Oncology: Festschrift in Honor of Richard P. BaumISBN: 9783031335327 ;ISBN: 3031335333 ;ISBN: 9783031335334 ;ISBN: 3031335325 ;DOI: 10.1007/978-3-031-33533-4Digital Resources/Online E-Resources |
|
4 |
Material Type: Article
|
A Drug-Target Interaction Prediction Based on Supervised Probabilistic ClassificationJournal of computer science, 2023-10, Vol.19 (10), p.1203-1211ISSN: 1549-3636 ;EISSN: 1552-6607 ;DOI: 10.3844/jcssp.2023.1203.1211Full text available |
|
5 |
Material Type: Article
|
Case report: Peptide receptor radioligand therapy in metastatic pediatric neuroendocrine tumorsFrontiers in nuclear medicine, 2023-08, Vol.3 [Peer Reviewed Journal]ISSN: 2673-8880 ;EISSN: 2673-8880 ;DOI: 10.3389/fnume.2023.1193880Full text available |
|
6 |
Material Type: Article
|
Optimization of Radiolabeling of a [ 90 Y]Y-Anti-CD66-Antibody for Radioimmunotherapy before Allogeneic Hematopoietic Cell TransplantationCancers, 2023-07, Vol.15 (14), p.3660 [Peer Reviewed Journal]2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;2023 by the authors. 2023 ;ISSN: 2072-6694 ;EISSN: 2072-6694 ;DOI: 10.3390/cancers15143660 ;PMID: 37509321Full text available |
|
7 |
Material Type: Article
|
India's Growing Nuclear Medicine Infrastructure and Emergence of Radiotheranostics in Cancer Care: Associated Challenges and the Opportunities to CollaborateIndian journal of nuclear medicine, 2023-07, Vol.38 (3), p.201-207 [Peer Reviewed Journal]Copyright: © 2023 Indian Journal of Nuclear Medicine 2023 ;ISSN: 0972-3919 ;EISSN: 0974-0244 ;DOI: 10.4103/ijnm.ijnm_77_23Full text available |
|
8 |
Material Type: Article
|
Optimization of Radiolabeling of a [[sup.90]Y]Y-Anti-CD66-Antibody for Radioimmunotherapy before Allogeneic Hematopoietic Cell TransplantationCancers, 2023-07, Vol.15 (14) [Peer Reviewed Journal]COPYRIGHT 2023 MDPI AG ;ISSN: 2072-6694 ;EISSN: 2072-6694 ;DOI: 10.3390/cancers15143660Full text available |
|
9 |
Material Type: Article
|
India's growing nuclear medicine infrastructure and emergence of radiotheranotics in cancer care: Associated challenges and the opportunities to collaborateIndian journal of nuclear medicine, 2023-07, Vol.38 (3), p.201-207 [Peer Reviewed Journal]COPYRIGHT 2023 Medknow Publications and Media Pvt. Ltd. ;2023. This article is published under (http://creativecommons.org/licenses/by-nc-sa/3.0/) (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;ISSN: 0972-3919 ;EISSN: 0974-0244 ;DOI: 10.4103/ijnm.ijnm_77_23Full text available |
|
10 |
Material Type: Article
|
Personalized [177Lu]Lutetium-PSMA Therapy for Patients with Pre-Treated Castration-Resistant Prostate Cancer: A Single Institution Experience from a Comprehensive Cancer CentreCancers, 2023-06, Vol.15 (12), p.3216 [Peer Reviewed Journal]COPYRIGHT 2023 MDPI AG ;2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;2023 by the authors. 2023 ;ISSN: 2072-6694 ;EISSN: 2072-6694 ;DOI: 10.3390/cancers15123216 ;PMID: 37370826Full text available |
|
11 |
Material Type: Article
|
Safety and Survival Outcomes of 177Lu-Prostate-Specific Membrane Antigen Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer with Prior 223Ra treatment: The RALU StudyThe Journal of nuclear medicine (1978), 2023-04, Vol.64 (4), p.574-578 [Peer Reviewed Journal]Copyright Society of Nuclear Medicine Apr 1, 2023 ;2023 by the Society of Nuclear Medicine and Molecular Imaging. 2023 ;ISSN: 0161-5505 ;EISSN: 1535-5667 ;DOI: 10.2967/jnumed.122.264456 ;PMID: 36302656Full text available |
|
12 |
Material Type: Article
|
Safety and Survival Outcomes of 177 Lu-Prostate-Specific Membrane Antigen Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer with Prior 223 Ra treatment: The RALU StudyJournal of Nuclear Medicine, 2023-04, Vol.64 (4), p.574-578 [Peer Reviewed Journal]2023 by the Society of Nuclear Medicine and Molecular Imaging. ;ISSN: 0161-5505 ;EISSN: 1535-5667 ;EISSN: 2159-662X ;DOI: 10.2967/jnumed.122.264456 ;PMID: 36302656Full text available |
|
13 |
Material Type: Article
|
Predictive and prognostic potential of pretreatment 68 Ga-PSMA PET tumor heterogeneity index in patients with metastatic castration-resistant prostate cancer (mCRPC)Journal of clinical oncology, 2023-02, Vol.41 (6_suppl), p.200-200 [Peer Reviewed Journal]ISSN: 0732-183X ;EISSN: 1527-7755 ;DOI: 10.1200/JCO.2023.41.6_suppl.200Full text available |
|
14 |
Material Type: Article
|
Time interval between radium-223 ( 223 Ra) therapy and Lutetium-177–prostate-specific membrane antigen ( 177 Lu-PSMA) treatment and outcomes in the RALU studyJournal of clinical oncology, 2023-02, Vol.41 (6_suppl), p.73-73 [Peer Reviewed Journal]ISSN: 0732-183X ;EISSN: 1527-7755 ;DOI: 10.1200/JCO.2023.41.6_suppl.73Full text available |
|
15 |
Material Type: Article
|
Predictive and prognostic potential of pretreatment 68Ga-PSMA PET tumor heterogeneity index in patients with metastatic castration-resistant prostate cancer treated with 177Lu-PSMAFrontiers in oncology, 2022-12, Vol.12, p.1066926-1066926 [Peer Reviewed Journal]Copyright © 2022 Assadi, Manafi-Farid, Jafari, Keshavarz, Divband, Moradi, Adinehpour, Samimi, Dadgar, Jokar, Mayer and Prasad 2022 Assadi, Manafi-Farid, Jafari, Keshavarz, Divband, Moradi, Adinehpour, Samimi, Dadgar, Jokar, Mayer and Prasad ;ISSN: 2234-943X ;EISSN: 2234-943X ;DOI: 10.3389/fonc.2022.1066926Full text available |
|
16 |
Material Type: Article
|
Poster PresentationIndian journal of nephrology, 2022-12, Vol.32 (7), p.19-166 [Peer Reviewed Journal]COPYRIGHT 2022 Medknow Publications and Media Pvt. Ltd. ;2022. This article is published under (http://creativecommons.org/licenses/by-nc-sa/3.0/) (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;ISSN: 0971-4065 ;EISSN: 1998-3662 ;DOI: 10.4103/0971-4065.362512Full text available |
|
17 |
Material Type: Article
|
Comparison of PSMA-TO-1 and PSMA-617 labeled with gallium-68, lutetium-177 and actinium-225EJNMMI research, 2022-10, Vol.12 (1), p.65-11, Article 65 [Peer Reviewed Journal]The Author(s) 2022 ;2022. The Author(s). ;The Author(s) 2022. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;ISSN: 2191-219X ;EISSN: 2191-219X ;DOI: 10.1186/s13550-022-00935-6 ;PMID: 36182983Full text available |
|
18 |
Material Type: Article
|
Editorial: Response assessment of radioligand therapiesFrontiers in oncology, 2022-07, Vol.12, p.904337-904337 [Peer Reviewed Journal]Copyright © 2022 Lopci and Prasad 2022 Lopci and Prasad ;ISSN: 2234-943X ;EISSN: 2234-943X ;DOI: 10.3389/fonc.2022.904337 ;PMID: 35965585Full text available |
|
19 |
Material Type: Article
|
Short-Interval, Low-Dose Peptide Receptor Radionuclide Therapy in Combination with PD-1 Checkpoint Immunotherapy Induces Remission in Immunocompromised Patients with Metastatic Merkel Cell CarcinomaPharmaceutics, 2022-07, Vol.14 (7), p.1466 [Peer Reviewed Journal]2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;2022 by the authors. 2022 ;ISSN: 1999-4923 ;EISSN: 1999-4923 ;DOI: 10.3390/pharmaceutics14071466 ;PMID: 35890361Full text available |
|
20 |
Material Type: Article
|
European Neuroendocrine Tumor Society (ENETS) 2022 Guidance Paper for Carcinoid Syndrome and Carcinoid Heart DiseaseJournal of neuroendocrinology, 2022-07, Vol.34 (7) [Peer Reviewed Journal]Distributed under a Creative Commons Attribution 4.0 International License ;ISSN: 0953-8194 ;ISSN: 1365-2826 ;EISSN: 1365-2826 ;DOI: 10.1111/jne.13146 ;PMID: 35613326Digital Resources/Online E-Resources |